SCHEMBL8255326

SCHEMBL8255326

C=CCc1c(-c2cccc(OC)c2)cn[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCTPP1 Q9H773 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TGFBR1 P36897 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ GFER P55789 1/20 0.43
▸ NOTUM Q6P988 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ TDO2 P48775 1/20 0.40
▸ GAA P10253 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ HTR7 P34969 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ HTR3A P46098 1/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ GRIN2D O15399 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067695 0.72 ALDH1A1 (0.54) ALDH1A1LMNATGFBR1NOTUMPKM
SCHEMBL4177085 0.71 MAPT (0.71) ALDH1A1LMNATGFBR1KDM4EGFER
SCHEMBL28656719 0.70 MGAT2 (0.43) ALDH1A1LMNAKDM4EGFERTDO2
SCHEMBL4979339 0.70 HTR7 (0.48) ALDH1A1LMNAKDM4EGFERTDO2
SCHEMBL5065634 0.69 GRIN1 (0.51) ALDH1A1LMNANOTUMGAAHTR1A
SCHEMBL8253681 0.68 MAPT (0.50) ALDH1A1LMNAKDM4EHTR1AHTR2C
SCHEMBL6132077 0.66 TGFBR1 (0.56) LMNATGFBR1GFERHTR1AHTR2A
SCHEMBL6132089 0.65 TDP1 (0.54) ALDH1A1LMNATGFBR1GFERPKM
SCHEMBL8220816 0.64 FYN (0.45) ALDH1A1KDM4ENOTUM
SCHEMBL29382328 0.64 ALDH1A1 (0.60) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350043-B2 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA, INC. (US) 2013-01-08 — — US disclosed
US-8350043-B2 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA, INC. (US) 2013-01-08 — — US disclosed
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-02-15 — — US disclosed
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2007-02-15 — — US disclosed
WO-2006133242-A2 AZINONE AND DIAZINONE V3 INHIBITORS FOR DEPRESSION AND STRESS DISORDERS PHARMACOPEIA, INC. (US) 2006-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037822-A1 Azinone and diazinone V3 inhibitors for depression and stress disorders HTR3C, HTR3A, AZI2 DCTPP1 3377/4885ALDH1A1 200/4885LMNA 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback